vimarsana.com
Home
Live Updates
Travere Therapeutics Reports Third Quarter 2023 Financial Re
Travere Therapeutics Reports Third Quarter 2023 Financial Re
Travere Therapeutics Reports Third Quarter 2023 Financial Results
Received 430 new patient start forms for FILSPARI® in the third quarter of 2023; demand and payer coverage continued to grow Net product sales of FILSPARI...
Related Keywords
United States ,
Iceland ,
Liechtenstein ,
Norway ,
American ,
Nivi Nehra ,
Deric Dube ,
Naomi Eichenbaum ,
Mirum Pharmaceuticals ,
American Society Of Nephrology Kidney Week ,
Travere Therapeutics Inc ,
Corporate Communications ,
European Union ,
Program Updates ,
Drug Administration ,
Committee For Medicinal Products Human Use ,
Exchange Commission ,
Mission Pharmacal Company ,
Nasdaq ,
European Medicines Agency ,
Week Late Breakers ,
Travere Total Care ,
Continuing Operations ,
Quarter Ended September ,
American Society ,
Nephrology Kidney Week ,
New England Journal ,
New Drug Application ,
Medicinal Products ,
Human Use ,
Conditional Marketing Authorization ,
Inborn Errors ,
Annual Symposium ,
Par Pharmaceutical ,
Acid Product Portfolio ,
Travere Therapeutics ,
Important Safety Information ,
Endothelin Receptor Antagonists ,
Upper Limit ,
Fetal Toxicity ,
Full Prescribing Information ,
Private Securities Litigation Reform Act ,
Months Ended September ,
Markets ,